HYPERVISCOSITY SYNDROME: NURSES' ROLE IN THE MANAGEMENT AND TREATMENT OF THIS ONCOLOGIC EMERGENCY

2.50
Hdl Handle:
http://hdl.handle.net/10755/165077
Category:
Abstract
Type:
Presentation
Title:
HYPERVISCOSITY SYNDROME: NURSES' ROLE IN THE MANAGEMENT AND TREATMENT OF THIS ONCOLOGIC EMERGENCY
Author(s):
Mullen, Ellen; Mendez, Noel; Mullen, Daniel
Author Details:
Ellen Mullen, RN, BSN, ANP, GNP, Advanced Practice Nurse, MD Anderson Cancer Center, Houston, Texas, USA, email: ellenmullen111@yahoo.com; Noel Mendez, RN, BSN, OCN; Daniel Mullen, RN, AND
Abstract:
Hyperviscosity syndrome (HVS) is a complication that is associated with plasma cell dyscrasias. Plasma cell dyscrasias is a group of related disorders such as Multiple Myeloma (MM), Waldenstrom's macroglobulinemia. It is seen approximately 2-10% in MM and 10-30% in WM. HVS is the term used to describe the clinical symptoms related to increased blood viscosity which is the result of increased circulating serum immunoglobulins produced by abnormal plasma cells. Increased viscosity can lead to tissue damage and even multi-organ failure. It is imperative that nurses are knowledgeable about this oncologic emergency in order to recognize its clinical presentations and facilitate immediate treatment, educate patients/families about this syndrome, and provide symptom management. The purpose of this presentation is to increase awareness of this emerging oncologic emergency. Clinical manifestations of HVS are the result of increased circulating serum immunoglobulins. The clinical presentation of HVS presents as a triad of mucosal bleeding, neurological abnormalities and vision abnormalities. Other presentations that have been reported are hearing loss, kidney failure, CHF and stroke. The immediate treatment of this oncologic emergency includes hydration with diuresis and plasmapheresis. Single plasmapheresis usually results in dramatic improvement in patients with WM but in MM, usually it requires more than one plasma exchange. The ultimate treatment of this syndrome is aim at controlling the underlying illness. In MM, the treatment may include XRT, steroids, thalidomide, and chemotherapy. In WM, the treatment may include monoclonal antibody such as rituximab and chemotherapy. After the presentation, nurses will be able to identify the clinical presentations of HVS. The nurse will be able to identify diagnostic tools for hyperviscosity syndrome. The nurse will be able to discuss the immediate and long term treatment of this oncologic emergency. The nurse will be able discuss symptom management of this patient population. The poster presentation will include brief overview of the pathogenesis, clinical features and treatment of Hyperviscosity Syndrome. The ultimate treatment of this syndrome is treating the underlying disease, so treatment of plasma cell dyscrasias most respectively, MM and WM will be briefly discussed. It is important that nurses stay current or updated with the treatment of MM and WM through research and continuing education programs.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2007
Conference Name:
32nd Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
Las Vegas, Nevada, USA
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titleHYPERVISCOSITY SYNDROME: NURSES' ROLE IN THE MANAGEMENT AND TREATMENT OF THIS ONCOLOGIC EMERGENCYen_GB
dc.contributor.authorMullen, Ellenen_US
dc.contributor.authorMendez, Noelen_US
dc.contributor.authorMullen, Danielen_US
dc.author.detailsEllen Mullen, RN, BSN, ANP, GNP, Advanced Practice Nurse, MD Anderson Cancer Center, Houston, Texas, USA, email: ellenmullen111@yahoo.com; Noel Mendez, RN, BSN, OCN; Daniel Mullen, RN, ANDen_US
dc.identifier.urihttp://hdl.handle.net/10755/165077-
dc.description.abstractHyperviscosity syndrome (HVS) is a complication that is associated with plasma cell dyscrasias. Plasma cell dyscrasias is a group of related disorders such as Multiple Myeloma (MM), Waldenstrom's macroglobulinemia. It is seen approximately 2-10% in MM and 10-30% in WM. HVS is the term used to describe the clinical symptoms related to increased blood viscosity which is the result of increased circulating serum immunoglobulins produced by abnormal plasma cells. Increased viscosity can lead to tissue damage and even multi-organ failure. It is imperative that nurses are knowledgeable about this oncologic emergency in order to recognize its clinical presentations and facilitate immediate treatment, educate patients/families about this syndrome, and provide symptom management. The purpose of this presentation is to increase awareness of this emerging oncologic emergency. Clinical manifestations of HVS are the result of increased circulating serum immunoglobulins. The clinical presentation of HVS presents as a triad of mucosal bleeding, neurological abnormalities and vision abnormalities. Other presentations that have been reported are hearing loss, kidney failure, CHF and stroke. The immediate treatment of this oncologic emergency includes hydration with diuresis and plasmapheresis. Single plasmapheresis usually results in dramatic improvement in patients with WM but in MM, usually it requires more than one plasma exchange. The ultimate treatment of this syndrome is aim at controlling the underlying illness. In MM, the treatment may include XRT, steroids, thalidomide, and chemotherapy. In WM, the treatment may include monoclonal antibody such as rituximab and chemotherapy. After the presentation, nurses will be able to identify the clinical presentations of HVS. The nurse will be able to identify diagnostic tools for hyperviscosity syndrome. The nurse will be able to discuss the immediate and long term treatment of this oncologic emergency. The nurse will be able discuss symptom management of this patient population. The poster presentation will include brief overview of the pathogenesis, clinical features and treatment of Hyperviscosity Syndrome. The ultimate treatment of this syndrome is treating the underlying disease, so treatment of plasma cell dyscrasias most respectively, MM and WM will be briefly discussed. It is important that nurses stay current or updated with the treatment of MM and WM through research and continuing education programs.en_GB
dc.date.available2011-10-27T12:12:06Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:12:06Z-
dc.conference.date2007en_US
dc.conference.name32nd Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationLas Vegas, Nevada, USAen_US
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.